logo
Plus   Neg
Share
Email

Pfizer Q2 Revenues Up 2% Operationally; Updates 2019 Guidance

Pfizer Inc. (PFE) said it reported solid second-quarter financial results, with total company revenues up 2% operationally. Performance was primarily driven by 6% volume-driven operational growth in the company's Biopharma business.

For the second-quarter, adjusted EPS was $0.80 compared to $0.77, a year ago. On average, ten analysts polled by Thomson Reuters expected the company to report profit per share of $0.75, for the quarter. Analysts' estimates typically exclude special items. Reported net income improved 30% year-on-year to $5.05 billion.

Second-quarter revenues totaled $13.26 billion, a decrease of 2%, compared to the prior-year quarter. Analysts expected revenue of $13.4 billion, for the quarter. Second-quarter Biopharma revenues totaled $9.6 billion, up 6% operationally. Upjohn revenues were $2.8 billion, down 7% operationally.

During the first six months of 2019, Pfizer returned $12.9 billion directly to shareholders, through a combination of: $4.0 billion of dividends; and $8.9 billion of share repurchases. As of July 30, 2019, Pfizer's remaining share repurchase authorization was $5.3 billion.

The company updated its 2019 financial guidance primarily to reflect the anticipated formation of the Consumer Healthcare Joint Venture with GlaxoSmithKline plc and the anticipated near-term completion of the Array BioPharma Inc. acquisition. Excluding the changes to guidance related to pending business development activities, the company's 2019 financial guidance is unchanged.

For 2019, Pfizer now projects adjusted EPS in a range of $2.76 to $2.86, updated from prior guidance range of $2.83 to $2.93. Revenues are anticipated to be in the range of
$50.5 billion to $52.5 billion, revised from previous guidance range of $52.0 billion to $54.0 billion. Analysts expect the company to report profit per share of $2.91 on revenue of $53.28 billion.

Separately, Pfizer and Mylan announced a definitive agreement to combine Upjohn and Mylan to create a new global pharmaceutical company. Pfizer shareholders would own 57% and Mylan shareholders would own 43% of the combined new company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
British luxury car giant Aston Martin unveiled its first SUV at an event in Los Angeles and at a simultaneous event in Beijing. The DBX SUV comes with an aluminium body with a typical Aston Martin grille flanked by LED headlights with LED DRLs. "I can't emphasize enough how incredibly exciting... Google has rolled out an audio news service for Google Assistant, called 'Your News Update,' which will read out a user's customized news feed. According to the tech giant, 'Your News Update' is a smarter way to listen to the news hosted by the Google Assistant. The customized news feed will deliver stories from a variety of media partners, including CBS, Politico, Fox News and CNN. The U.S. Securities and Exchange Commission said it has filed an emergency action and received a temporary restraining order and asset freeze against two Florida residents as well as the two companies controlled by them for an alleged $6 million Ponzi scheme. The Ponzi scheme by Neil Burkholz of Boca Raton, Florida, and Frank Bianco of Pembroke Pines, Florida, defrauded at least 55 investors.
Follow RTT
>